Company Overview - Angel Yeast Co., Ltd. is located at 168 Chengdong Avenue, Yichang City, Hubei Province, established on March 25, 1998, and listed on August 18, 2000. The company primarily engages in the development, production, and operation of yeast, yeast derivatives, and related biological products [1] - The main business revenue composition includes yeast and related industries at 90.62%, other at 7.89%, and packaging materials at 4.07% [1] Financial Performance - For the first half of 2025, Angel Yeast achieved operating revenue of 7.899 billion yuan, a year-on-year increase of 10.10%, and a net profit attributable to shareholders of 799 million yuan, a year-on-year increase of 15.66% [2] - Since its A-share listing, Angel Yeast has cumulatively distributed cash dividends amounting to 3.961 billion yuan, with 1.341 billion yuan distributed in the last three years [3] Stock Market Activity - As of September 17, Angel Yeast's stock price decreased by 2.06%, trading at 39.51 yuan per share, with a total market capitalization of 34.3 billion yuan [1] - Year-to-date, the stock price has increased by 11.30%, with a recent decline of 3.80% over the last five trading days [1] - The company has appeared on the "Dragon and Tiger List" once this year, with the most recent appearance on March 5, where it recorded a net buy of -136 million yuan [1] Shareholder Information - As of June 30, the number of shareholders for Angel Yeast was 63,900, a decrease of 5.74% from the previous period, with an average of 13,411 circulating shares per person, an increase of 6.42% [2] - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 36.9082 million shares, an increase of 1.3394 million shares from the previous period [3]

Core Viewpoint - New Dairy Industry's stock price has shown fluctuations with a year-to-date increase of 26.12%, while recent trading indicates a slight decline over the past five days [1] Financial Performance - For the first half of 2025, New Dairy achieved a revenue of 5.526 billion yuan, representing a year-on-year growth of 3.01%, and a net profit attributable to shareholders of 397 million yuan, reflecting a significant increase of 33.76% [2] Stock Market Activity - As of September 17, New Dairy's stock price was 17.94 yuan per share, with a market capitalization of 15.441 billion yuan. The stock experienced a trading volume of 50.6096 million yuan and a turnover rate of 0.34% [1] - The stock has been on the龙虎榜 once this year, with the last appearance on April 10, where it recorded a net purchase of 67.0816 million yuan [1] Shareholder Information - As of September 10, the number of shareholders for New Dairy was 16,800, a decrease of 3.70% from the previous period, with an average of 50,691 circulating shares per shareholder, an increase of 3.84% [2] - The top ten circulating shareholders include various funds, with notable changes in holdings among them [3]

Company Overview - San Yuan Foods Co., Ltd. is located in Daxing District, Beijing, established on March 13, 1997, and listed on September 15, 2003. The company primarily engages in the production and sales of dairy and dairy products [1]. - The main business revenue composition includes liquid milk (59.83%), ice cream and others (26.58%), and solid milk (13.58%) [1]. Stock Performance - As of September 17, the stock price of San Yuan dropped by 2.02%, trading at 4.86 CNY per share, with a total market capitalization of 7.335 billion CNY [1]. - Year-to-date, the stock price has increased by 10.76%, with a decline of 3.57% over the last five trading days, a rise of 1.89% over the last 20 days, and an increase of 7.81% over the last 60 days [1]. Financial Performance - For the first half of 2025, San Yuan reported a revenue of 3.331 billion CNY, a year-on-year decrease of 13.52%. However, the net profit attributable to shareholders increased by 42.65% to 183 million CNY [2]. - The company has distributed a total of 317 million CNY in dividends since its A-share listing, with 104 million CNY distributed in the last three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 10.14% to 34,500, while the average circulating shares per person increased by 11.29% to 43,384 shares [2]. - Hong Kong Central Clearing Limited is the sixth-largest circulating shareholder, holding 7.4102 million shares, an increase of 624,900 shares compared to the previous period [3].

Core Viewpoint - Furuya Co., Ltd. has shown significant stock price growth in 2023, with a year-to-date increase of 166.30% and a recent surge of 31.98% over the past five trading days [2] Group 1: Stock Performance - As of September 16, Furuya's stock price reached 83.99 CNY per share, with a market capitalization of 22.255 billion CNY [1] - The stock has experienced a 16.28% increase over the past 20 days and a remarkable 167.14% increase over the past 60 days [2] - The company has appeared on the trading leaderboard twice this year, with the latest instance on September 15, where it recorded a net buy of 74.2524 million CNY [2] Group 2: Financial Performance - For the first half of 2025, Furuya reported a revenue of 713 million CNY, reflecting a year-on-year growth of 11.02%, while the net profit attributable to shareholders decreased by 31.09% to 51.934 million CNY [2] - Cumulatively, the company has distributed 246 million CNY in dividends since its A-share listing, with 52.6106 million CNY distributed over the past three years [3] Group 3: Shareholder Information - As of June 30, 2025, Furuya had 25,600 shareholders, an increase of 6.91% from the previous period, with an average of 9,108 circulating shares per shareholder, down by 6.47% [2] - The second-largest circulating shareholder is Huabao Zhongzheng Medical ETF, holding 8.7128 million shares, an increase of 947,800 shares from the previous period [3]

Core Viewpoint - The stock of TuoJing Life has experienced significant fluctuations, with a year-to-date increase of 88.23%, indicating strong market interest despite recent declines in share price and financial performance [1][2]. Financial Performance - For the first half of 2025, TuoJing Life reported revenue of 159 million yuan, a year-on-year decrease of 26.25%, and a net profit attributable to shareholders of 2.76 million yuan, down 58.41% compared to the previous year [2]. - Cumulative cash dividends since the company's A-share listing amount to 264 million yuan, with 81.36 million yuan distributed over the past three years [3]. Stock Market Activity - As of September 16, TuoJing Life's stock price was 26.30 yuan per share, with a market capitalization of 4.275 billion yuan. The stock has seen a trading volume of 96.61 million yuan and a turnover rate of 2.63% [1]. - The stock has experienced a net outflow of 2.24 million yuan in principal funds, with significant buying and selling activity from large orders [1]. Shareholder Information - As of June 30, 2025, the number of shareholders for TuoJing Life was 16,000, a decrease of 6.19% from the previous period, while the average number of circulating shares per person increased by 6.60% to 8,614 shares [2]. - Among the top ten circulating shareholders, CITIC Prudential Multi-Strategy Mixed Fund (LOF) A is a new entrant, holding 1.20 million shares [3]. Business Overview - TuoJing Life, established on November 6, 2003, and listed on April 21, 2017, specializes in the research, production, and sales of in vitro diagnostic products, with 92.50% of its revenue coming from reagent sales [1]. - The company operates within the pharmaceutical and biotechnology sector, specifically in medical devices and in vitro diagnostics [1].

Company Overview - Qisheng Technology Co., Ltd. is located in Jiaxing City, Zhejiang Province, and was established on October 19, 2005. The company was listed on October 29, 2019. Its main business involves the research, design, production, and sales of smart electric beds and related products [1][2]. Financial Performance - For the first half of 2025, Qisheng Technology achieved operating revenue of 1.459 billion yuan, a year-on-year increase of 0.07%. The net profit attributable to the parent company was 106 million yuan, reflecting a year-on-year growth of 24.18% [2]. - Since its A-share listing, Qisheng Technology has distributed a total of 754 million yuan in dividends, with 388 million yuan distributed over the past three years [3]. Stock Performance - As of September 15, Qisheng Technology's stock price increased by 2.08%, reaching 17.15 yuan per share, with a trading volume of 152 million yuan and a turnover rate of 2.56%. The total market capitalization is 6.054 billion yuan [1]. - Year-to-date, the stock price has risen by 37.07%, with a 1.24% increase over the last five trading days, a 15.26% increase over the last 20 days, and a 47.08% increase over the last 60 days [1]. Shareholder Information - As of June 30, the number of shareholders for Qisheng Technology was 31,100, an increase of 44.74% compared to the previous period. The average number of circulating shares per person decreased by 31.97% to 11,353 shares [2]. - As of June 30, 2025, Hong Kong Central Clearing Limited has exited the list of the top ten circulating shareholders [3]. Business Segmentation - The main revenue composition of Qisheng Technology includes smart electric beds (80.92%), accessories and others (8.33%), mattresses (7.38%), and other supplementary products (3.37%) [1].

Core Viewpoint - David Medical's stock has experienced fluctuations, with a recent decline despite a year-to-date increase, indicating potential volatility in the market [1][2]. Company Overview - David Medical, established on September 18, 1992, and listed on May 8, 2012, is located in Xiangshan, Ningbo, Zhejiang Province. The company specializes in the research, production, and sales of infant care equipment [2]. - The main revenue sources are: 51.93% from obstetric and pediatric care equipment, 45.88% from minimally invasive surgical instruments, and 2.18% from other products [2]. Stock Performance - Year-to-date, David Medical's stock price has increased by 31.03%. However, it has seen a decline of 3.17% over the last five trading days and 1.61% over the last 20 days. In contrast, the stock rose by 21.36% over the past 60 days [2]. - As of September 15, the stock price was reported at 14.64 CNY per share, with a market capitalization of 4.216 billion CNY [1]. Financial Performance - For the first half of 2025, David Medical reported a revenue of 251 million CNY, a year-on-year decrease of 5.48%. However, the net profit attributable to shareholders increased by 9.57% to 50.9767 million CNY [2]. Shareholder Information - As of August 29, the number of shareholders was 22,400, a decrease of 2.18% from the previous period. The average number of circulating shares per person increased by 2.23% to 6,417 shares [2]. - The company has distributed a total of 342 million CNY in dividends since its A-share listing, with 120 million CNY distributed in the last three years [3]. Institutional Holdings - As of June 30, 2025, among the top ten circulating shareholders, Jin Yuan Shun An Yuan Qi Ling Huo Pei Zhi Mixed Fund (004685) is the fourth largest with 900,000 shares, and Yuan Xin Yong Feng Ju You A (010469) is the fifth largest with 882,000 shares, both being new shareholders [3].

Core Viewpoint - New Hope Dairy's stock price has shown fluctuations, with a year-to-date increase of 26.19% but a recent decline of 1.27% over the last five trading days [1] Financial Performance - For the first half of 2025, New Hope Dairy achieved a revenue of 55.26 billion, representing a year-on-year growth of 3.01%, while the net profit attributable to shareholders was 3.97 billion, up 33.76% year-on-year [2] Stock Market Activity - As of September 12, New Hope Dairy's stock was trading at 17.95 per share, with a total market capitalization of 154.49 billion [1] - The stock has seen a net outflow of 225.89 million in principal funds, with significant selling activity [1] - The company has appeared on the trading leaderboard once this year, with a net buy of 67.08 million on April 10 [1] Shareholder Information - As of August 29, the number of shareholders increased to 17,400, with an average of 48,818 circulating shares per person [2] - The company has distributed a total of 6.76 billion in dividends since its A-share listing, with 4.48 billion in the last three years [3] Institutional Holdings - As of June 30, 2025, major shareholders include China Europe Value Select Mixed A, which reduced its holdings by 1.59 million shares, and Hong Kong Central Clearing Limited, which is a new shareholder with 4.50 million shares [3]

Company Overview - Baiyang Pharmaceutical Co., Ltd. is located in Qingdao, Shandong Province, established on March 8, 2005, and listed on June 30, 2021 [1] - The company provides comprehensive commercialization solutions for pharmaceutical product manufacturers, including brand operation, wholesale distribution, and retail, with a focus on marketing solutions for branded pharmaceutical manufacturers [1] Financial Performance - As of June 30, 2025, Baiyang Pharmaceutical achieved a revenue of 3.751 billion yuan, representing a year-on-year growth of 4.36%, while the net profit attributable to shareholders decreased by 55.75% to 163 million yuan [2] - The company has distributed a total of 1.551 billion yuan in dividends since its A-share listing, with 1.201 billion yuan distributed over the past three years [3] Stock Performance - On September 12, Baiyang Pharmaceutical's stock price decreased by 2.01%, trading at 30.72 yuan per share, with a market capitalization of 16.147 billion yuan [1] - The stock has increased by 31.01% year-to-date, with a 13.11% rise over the last five trading days, 17.34% over the last 20 days, and 55.70% over the last 60 days [1] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 15% to 18,800, with an average of 27,926 circulating shares per shareholder, a decrease of 13.05% [2] - Among the top ten circulating shareholders, ICBC Frontier Medical Stock A (001717) ranked as the eighth largest, holding 2.6816 million shares, a decrease of 3.4767 million shares from the previous period [3] Market Position - Baiyang Pharmaceutical operates within the pharmaceutical and biological industry, specifically in the pharmaceutical commercial and distribution sector, and is associated with concepts such as online marketing, high dividends, and financing [2]

Company Overview - Hangzhou Xie Bai Group Co., Ltd. is located at 208 Huan Cheng North Road, Hangzhou, Zhejiang Province, established on October 30, 1992, and listed on January 14, 1994. The company's main business includes retail and wholesale of goods, hotels, import and export trade, and services [1][2]. Financial Performance - For the first half of 2025, Hangzhou Xie Bai reported operating revenue of 878 million yuan, a year-on-year decrease of 5.75%. The net profit attributable to the parent company was 150 million yuan, down 23.48% year-on-year [2]. - Since its A-share listing, the company has distributed a total of 1.245 billion yuan in dividends, with 301 million yuan distributed over the past three years [3]. Stock Performance - As of September 11, the stock price of Hangzhou Xie Bai decreased by 2.07%, trading at 8.03 yuan per share, with a total market capitalization of 5.903 billion yuan. The stock has seen a year-to-date decline of 1.51% [1]. - The stock has appeared on the "Dragon and Tiger List" once this year, with the most recent appearance on February 20, where it recorded a net purchase of 7.6322 million yuan [1]. Shareholder Information - As of June 30, 2025, the number of shareholders for Hangzhou Xie Bai was 32,400, a decrease of 1.61% from the previous period. The average circulating shares per person increased by 1.64% to 22,488 shares [2]. - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 19.1461 million shares, which is a decrease of 10.638 million shares compared to the previous period [3]. Industry Classification - Hangzhou Xie Bai belongs to the Shenwan industry classification of retail trade, specifically general retail and department stores. The company is associated with several concept sectors, including multi-child concept, state-owned enterprise reform, Zhejiang state-owned assets, sports industry, and shared economy [2].